EGFR and adenocarcinoma: Of the 886 patients included, most were female (67.2%, n = 499/743), non-smokers (73.8%; n = 498/675), had adenocarcinoma (97.9%; n = 571/583), and received EGFR-TKI rechallenge as a third-line therapy (82.9%; n = 561/677).